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Received June 27, 2012; accepted August 10, 2012AbstractBackground: The role of estrogen in the growth and survival of ovarian cancer cells is controversial. In this study, we investigated the changes in
cell-cycle regulatory proteins in ovarian cancer cell lines after estrogen treatment to explore the role of estrogen in ovarian cancers.
Methods: Two ovarian adenocarcinoma cell lines were used for the study: the first, OC-117-VGH, was deficient in estrogen receptors (ER)a and
ERb, and the second, OVCAR3, was positive for ERa and ERb. Serial concentrations of estrogen were used to evaluate the effects of estrogen
on the survival of ovarian cancer cells. The cell-cycle regulatory proteins, including cyclin D1, cyclin E, p16/INK4a, and p27/KIP1, were used to
check the possible mechanism of an estrogen effect on survival of the cancer cell line.
Results: Estrogen 0.01e1.0 mM inhibited the growth of both cell lines. There were no differences in cyclin D1 and E expression between the two
cell lines after estrogen treatment, but the expression of p16/INK4a and p27/KIP1 was significantly higher in the OC-1170-VGH cell line than in
the OVCAR3 cell line.
Conclusion: Although the ER-positive and ER-negative ovarian cancer cell lines were inhibited by estrogen, the influence of cell-cycle regu-
latory proteins was different between the two, suggesting that the inhibitory effect of estrogen on ovarian cancer cell lines might be mediated
through different pathways.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Ovarian cancer is the leading cause of cancer mortality in
female patients in Taiwan.1,2 The standard treatment for ovarian
cancer is an extensive surgical resection of the primary tumor and
all visible tumors in the abdominal cavity, followed by post-
operative adjuvant carboplatin and paclitaxel chemotherapy.3e5* Corresponding author. Dr. Kuan-Chong Chao, Department of Obstetrics
and Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai
Road, Taipei 112, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2012.08.023A resistance to chemotherapy usually suggests a poor
prognosis.6e8 Therefore, any agent other than platinums and the
taxanes regimen that might increase the response or survival of
women with ovarian cancer would be well received.9e12 For
example, recent epidemiologic studies have suggested that
estrogen might promote ovarian tumor progression in post-
menopausal women.13 This is supported by theWomen’s Health
Initiative (WHI) randomized trial.14,15 There is a growing body
of experimental evidence that estrogen may play important roles
in ovarian carcinogenesis, including the control of cellular
differentiation and growth, and in the apoptosis of ovarian cancer
cells.16 However, the exact nature of these roles remains thehinese Medical Association. All rights reserved.
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responsive to hormone therapy.18 Although the cause of this lack
of responsiveness is still uncertain, the loss of estrogen receptor
(ER) might be one reason.19,20
Estrogen signaling is mediated by receptor binding in the
nucleus, including fos, myc, and cyclin D.21 Cyclins, including
cyclin D1,22e25 cyclin E,23,25 p16/INK4a,26 and p27/KIP1,27
are cell-cycle regulatory proteins that are important factors
in cell cycles, and are the essential protein for the cell
differentiation process.22 The relationship between cell-cycle
regulatory proteins and the ER-mediated effect has been
reported.27 For example, p16/INK4a, and p27/KIP1 were
reported to influence the cancer behavior-invasiveness of
endometrial cells through ER,27 suggesting the possibility that
these cell-cycle regulatory proteins could be involved in
gynecologic cancer cells, especially hormone-related gyne-
cologic cancers, which may be mediated through an ER
pathway; therefore, the question can be raised as to whether
estrogen or other hormones could be used in the management
of various kinds of gynecologic cancers.
In the current study, we used an established ovarian
adenocarcinoma cell line, OC-117-VGH, which is negative for
ERa and ERb, and OVCAR3, which is positive for ERa and
ERb to investigate the effect of estrogen on ovarian cancer cell
lines, including their growth and the related cell-cycle regu-
latory proteins.
2. Methods2.1. Cell line and cultureAn ovarian adenocarcinoma cell line, OC-117-VGH, was
initiated from a clear-cell adenocarcinoma that had been
removed from a 56-year-old woman who underwent debulking
surgery for surgicopathologic stage IIIC ovarian cancer in
1997.16 Human ovarian cancer cells (OVCAR3; American
Type Culture Collection, Manassas, VA, USA) were also used
in this study. Both cells were grown in culture medium con-
taining a 1:1 mixture of F-12/DMEM (GIBCO BRL, Grand
Island, NY, USA), supplemented with 10% fetal calf serum
(FBS, HyClone, Logan, UT, USA), 100 U/mL penicillin,
100 mg/mL streptomycin, and 2.5 mg/mL amphotericin B. The
cells were incubated at 37C with 5% carbon dioxide with
greater than 95% humidity. The cell culture media were
changed twice a week and the cells were subcultured weekly
by detachment with 2.5 mg/mL trypsin/0.02% ethyl-
enediaminetetraacetic acid (EDTA) in Dulbecco’s phosphate-
buffered saline (D-PBS) solution (Gibco BRL, Grand Island,
NY, USA). Cells were maintained and subcultured weekly and
split at a 1:2 to 1:4 ratio in preparation for subsequent studies.2.2. Expression of ERa and ERb by reverse transcription
polymerase chain reactionWe used the TRIzol kit (Tel-Test Inc., Friendswood, TX,
USA) to purify the RNA of the ovarian cancer cells. We added
1 mL of TRIzol solution to the drug-treated ovarian cancercells after centrifugation at 12,500 rpm and 4C for 30
minutes, collected the upper layer and added isopropanol after
another centrifugation at 12,500 rpm and 4C for 30 minutes,
and then washed the RNA twice with 70% alcohol.
We used SuperScript First-Strand Syn (Gibco) reverse-
transcript RNA to complementary DNA (cDNA), following
the manufacturer’s protocol, by incubating 1 mg of total RNA
with oligo-d(T)12-18 (Invitrogen, Carlsbad, CA, USA) as the
initiation primer in a final reaction volume of 20 mL, which has
been described elsewhere.28e30
The primers used for detecting genes by the polymerase
chain reaction (PCR) method are as follows. The ERa was
amplified using the forward primer 50-TGCCAAGGAGAC
TCGCTA-30 and reverse primer 50-TCAACATTCTCCCTCC
TC-30(11) (amplicon length, 263 base pairs [bp]). The ERb
was amplified using the forward primer 50-GTCCATCGC
CAGTTATCACATC-30 and reverse primer 50-GCCTTACA
TCCTTCACACGA-30 (amplicon length, 242 bp).16 The PCR
buffer contained 1 mRNA selective PCR buffer, 5 mM
MgCl2, 1 mM deoxyribonucleoside triphosphate (dNTP)/
analog mixture, 2.5 U/mL avian myeloblastosis virus (AMV)-
optimized Taq polymerase, and 0.4 mM sense- and antisense-
specific primers. A total of 5 mL cDNA from each cell and
sterile distilled water was added to adjust the final concen-
tration to 50 mL. All transcripts were analyzed in a DNA
thermal cycler (PerkineElmer, Norwalk, CT, USA) with the
following cycle: a denaturation step of 85C for 1 minute, an
annealing step of 50C for 1 minute, and an extension step of
72C for 1 minute, repeated for 30 cycles, then a final primer
extension step of 72C for 5 minutes. PCR products were
analyzed by electrophoresis through a 2% agarose gel and
visualized by Sybr green II (Amersham Pharmacia USA)
staining under ultraviolet illumination.312.3. Estrogen treatmentAliquots (100 mL) containing 1 106 cells/mL were
dispensed into a 96-well plate (Corning Inc, Big Flats, NY, USA).
Triplicate cultures for each test were incubated for 24 hours at
37C, and then 100 mL of different concentrations of estrogen
were added.16 Estrogen was added separately to the final
concentrations, ranging from0.01 to 1.0 mM,prepared in a serum-
free medium. A serum-free culture medium was used for the
control. Cellswere treatedwith estrogen 0.01e1.0 mMfor 24, 48,
and 72 hours at 37C, with 5%CO2 andmore than 95%humidity.2.4. Cell survival assayCell proliferation assayswere automated by adopting a color-
based cell proliferation detection assay and a 96-well plate
culture system. The number of viable cells present was assessed
with the CellTiter 96 Aqueous (CTAQ) nonradioactive cell
proliferation assay system (Promega, Madison, WI, USA).16
This colorimetric assay determines the number of viable cells
on the basis of the conversion of the tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] into a formazan that is soluble in
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treatment, we added 20 mL per well of CTAQ. At the end, we
read the plate with a multiscan (Multiscan, Labsystems, Hel-
sinki, Finland) at an optical density of 490 nm.
Results were expressed as a percentage of cell survival after
estrogen treatment in culture media, and compared with the
controls. The estrogen-treated survival rates at each concen-
tration were calculated as follows:Survival rate relative to controlð%Þ ¼ Absorbance of treated wellsmean absorbance of background
Absorbance of control wellsmean absorbance of background 100%Protein concentrations were measured by the Lowry
method.32,332.5. Enzyme-linked immunosorbent assay detectionTo further dissect the role of cell-cycle regulatory proteins
in the ovarian cancer cell lines when estrogen was used with
these ovarian cancer cell lines, the expression of p16/INK4a,
p27/KIP1, cyclin D1, and cyclin E was determined by an
enzyme-linked immunosorbent assay (ELISA) of the estrogen-
treated cells.
After 24, 48, and 72 hours of estrogen treatment, cells were
washed with PBS and fixed in 75% ethanol for 10 minutes.
This was followed by incubation with acetic acid 0.03% in
a phosphate buffer solution for 30 minutes. Nonspecific
binding sites were blocked with normal goat serum (DAKO,
Glostrup, Denmark), and diluted 1:20 in Tris-buffered saline
for 30 minutes at room temperature.
The cells were then reacted with the following antibodies
and working dilutions: mouse anti-p16Mts1 clone G175e405
(BD Pharmingen, Hamburg, Germany; 1:1000), mouse anti-
p27, clone 1B4 (Novocastra; 1:50), rabbit anticyclin E (M-
20; Santa Cruz Biotechnology, Heidelberg, Germany), and
rabbit anti-cyclin D1 (H-295; Santa Cruz Biotechnology;
1:100) for 60 minutes at 37C. After washing, cells were then
reacted with goat antimouse or goat antirabbit alkaline
phosphatase-labeled secondary antibodies (Dako Cytomation
California Inc, Carpinteria, CA, USA; 1:500 diluted) for
another 60 minutes at 37C. Finally, the cells were incubated
with 7 mM of p-nitrophenyl phosphate (Sigma-Aldrich Corp,
St Louis, MO, USA) in a 0.01 M sodium bicarbonate buffer,
pH 10.0, for 30 minutes, then read by a Multiscan (Labsys-
tems) at an optical density of 410 nm.
The expression of p16/INK4a, p27/KIP1, cyclin D1, and
cyclin E at each condition was calculated as follows:Percentage relative to controlð%Þ ¼ Absorbance of treated wells
Absorbance of control wells2.6. Statistical analysisStatistical analysis of the data was performed with Statis-
tica version 5.1 (StatSoft Holdings Inc, Tulsa, OK, USA) and
SPSS version 12.0 (SPSS Inc, Chicago, IL, USA). Every
experiment was repeated six times. Experimental data were
presented as mean standard deviation, using the Dunnet test.
Statistical analysis was performed by repeated analysis ofvariance (ANOVA), with a post hoc test for between-group
analysis. A p value less than 0.05 was considered statisti-
cally significant.3. Results3.1. Expression of ERa and ERbWe used MCF7 breast cancer and DU145 prostate cancer
cells for positive control of ERa and ERb, as mentioned.16
There was neither ERa nor ERb mRNA expression in OC-
117-VGH. By contrast, both ERa and ERb were identified in
OVCAR3 (Fig. 1).3.2. Inhibition effect of estrogen on cell proliferation of
ovarian cellsWe first evaluated the survival rate of OC-117-VGH and
OVCAR3 ovarian adenocarcinoma cell lines treated with
different concentrations of estrogen. The concentrations of
estrogen in the culture medium ranged from 0.01 mM to
1.0 mM. The survival of both cancer cells in this study was
significantly impaired when using the estrogen treatment.
Even at the low concentration of 0.01 mM of estrogen, only
60% of the cancer cells survived (Fig. 2), independent of the
presence or absence of ERa or ERb. In addition, this impaired
survival of the ovarian cancer cell line seemed to be estrogen
dose-dependent, when the concentration of estrogen was less
than 0.1 mM, although this dose-dependent difference seemed
to be less significant between 0.01 mM and 1.0 mM. Both cell
lines also showed a time-dependent effect of estrogen on
cancer cell survival (Fig. 3), although the time-dependent
effect of estrogen on ER-positive OVCAR3 cancer cells
seemed to be less significant. The longer the OC-117-VGHmean absorbance of background
mean absorbance of background
 100%
Fig. 3. Time effect of estrogen (0.1 mM) on the survival rate (n¼ 6).
Fig. 1. Expression of ERa and ERb in the two ovarian cancer cell lines.
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the effect on cancer cell survival (Fig. 3).3.3. Expression of cyclin D1 and E in estrogen-treated
ovarian cancer cell linesThe expression of cyclin D1 and E of both ovarian cancer
cells treated with different concentrations (0.01e1.0 uM) of
estrogen are shown in Figs. 4 and 5. Although the expression
of cyclin D1 or cyclin E seemed to trend toward an increase
when the concentration of estrogen increased from 0.01 mM to
1.0 mM, respectively (Figs. 4 and 5), and this trend seemed to
differ between OC-117-VGH and OVCAR3 cells, the
increased cyclin D1 expression was more prominent in the
ER-negative OC-117-VGH cells; by contrast, the increased
cyclin E expression was more prominent in the ER-positive
OVCAR3 cells. However, neither were statistically signifi-
cant (Figs. 4 and 5, both p> 0.05), suggesting that estrogen
might not affect cyclin D1 and E expression when these
ovarian cancer cell lines were treated with different concen-
trations, ranging from 0.01 mM to 1.0 mM of estrogen.
The cyclin D1 and E expression of both ovarian cancer
cells treated with durations of estrogen ranging from 24 to 72
hours is shown in Figs. 6 and 7. A pattern similar to the one
previously described was noted in this time-dependent study.
Although the expression of cyclin D1 and E seemed to trendFig. 2. Dose effect of estrogen (24 hours) on the survival rate (n¼ 6).toward an increase compared to the control and cyclin E was
more prominent in the ER-positive OVCAR3 cells than in the
ER-negative OC-117-VGH cells, and by contrast, the cyclin
D1 was prominent in the ER-negative OC-117-VGH cells,
neither reached statistical significance (Figs. 6 and 7, both
p> 0.05). These data suggest that estrogen might not affect
cyclin D1 and E expression when these ovarian cancer cell
lines are treated with estrogen for durations ranging from 24
hours to 72 hours.3.4. Expression of p16/INK4a and p27/KIP1 in estrogen-
treated ovarian cancer cell linesThe expression of p16/INK4a, and p27/KIP1 of both
ovarian cancer cells treated with different concentrations
(0.01e1.0 mM) of estrogen are shown in Figs. 8 and 9. The
expression of p16/INK4a showed a significant increase (40%)
in the ER-negative OC-117-VGH cells when the concentration
of estrogen was increased from 0.01 mM to 1.0 mM (Fig. 8).
However, the p16/INK4a expression of the ER-positive
OVCAR3 did not show a change with different concentra-
tions of estrogen treatment. For the expression of p27/KIP1,
a similar finding was noted in the ER-negative OC-117-VGH
cells, i.e., a progressively increased expression of p27/KIP1Fig. 4. Dose effect of estrogen (24 hours) on the expression of cyclin D1
(n¼ 6).
Fig. 7. Time effect of estrogen (0.1 mM) on the expression of cyclin E (n¼ 6).
Fig. 5. Dose effect of estrogen (24 hours) on the expression of cyclin E (n¼ 6).
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from 0.01 mM to 1.0 mM (Fig. 9). The expression of p27/KIP1
was also similar to that of p16/INK4a in the ER-positive
OVCAR3 cells (Fig. 9).
The expression of p16/INK4a and p27/KIP1 of both
ovarian cancer cells treated with estrogen ranging from 24
hours to 72 hours is shown in Figs. 10 and 11. The expression
of p16/INK4a was significantly increased (almost 50%) in the
ER-negative OC-117-VGH cells when the time exposure to
estrogen was increased from 0 hours to 72 hours (Fig. 10);
however, the expression of p16/INK4a was also increased in
the ER-positive OVCAR3 cells, although the increase was not
statistically significant (Fig. 10).
A similar finding was noted in the ER-negative OC-117-
VGH cells; i.e., a time-dependent increased expression of
p27/KIP1 was seen in the ER-negative OC-117-VGH cells
(Fig. 11); however, the ER-positive OVCAR3 cells did not
show a change of expression of p27/KIP1, even though the
time exposure reached 72 hours (Fig. 11).
These results show that the response of the four cell-cycle
regulatory proteins, including cyclin D1, cyclin E, p16/INK4a,
and p27/KIP1 in the OC-117-VGH (negative for ERa and
ERb) cells or the OVCAR3 (positive for ERa and ERb) cellsFig. 6. Time effect of estrogen (0.1 mM) on the expression of cyclin D1
(n¼ 6).was different, and although estrogen did inhibit growth in both
cell lines, this inhibitory effect might not be always mediated
through the classic estrogen-ER pathway.
4. Discussion
Although the origin of ovarian tumor is still uncertain,
epithelial ovarian cancers appear to arise from the ovarian
surface epithelium.34 Repeated ovulation, which requires
cyclic destruction and repair of the ruptured ovarian surface
epithelium, is supposed to be one of the possible mechanisms
contributing to the neoplastic transformation of the ovarian
surface epithelium.35 Therefore, it has been suggested that
endocrine and autocrine factors may influence the occurrence
of ovarian tumors.16 The WHI study showed an increased risk
of ovarian cancer in women who were long-term users of
estrogen and progesterone.14,15 However, some articles re-
ported contradictory results,36e38 which may be due to
differences in methodology and the existence of uncontrolled
confounding factors.16
There is no doubt that estrogens might be one of the
causative factors of ovarian cancer,39 because estrogen levels
are more than 100-fold greater within the ovarian tissue andFig. 8. Dose effect of estrogen (24 hours) on the expression of p16 (n¼ 6).
Fig. 9. Dose effect of estrogen (24 hours) on the expression of p27 (n¼ 6). Fig. 11. Time effect of estrogen (0.1 mM) on the expression of p27 (n¼ 6).
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Some studies have found a stimulatory effect of estrogen on
the growth of normal and malignant ovarian surface epithe-
lium cells.40 These mitogenic effects are mediated through
activation of the interleukin-6/signal transducer and activation
of the transcription-3 (STAT-3) signaling pathway, and ovarian
cancer cells express high levels of constitutively activated
STAT-3, a known transforming cellular molecule.41
In the previous study, we indicated one of the possible
mechanisms to explain estrogen-impaired tumor survival in the
OC-117-VGH ovarian cancer cell line. This mechanism was the
downregulation of antiapoptotic Bcl-2 and proapoptotic Bax
proteins, especially, and more significantly, the declined
expression of Bcl-2, which contributed to the net effect of
reduced survival of this ER-negative ovarian cancer cell line.16
The cell cycle progression control should be coordinated by
many protein factors, including cyclins, cyclin-dependent
kinases (CDKs), and cyclin-dependent kinase inhibitors
(CKIs), and this coordination of cell cycle control is related to
tumor cell proliferation, differentiation, and apoptosis.42 In
this study, we evaluated the changes in cell-cycle inhibitory
proteinsdp16/INK4a and p27/KIP1, and cell-cycle stimula-
tory proteinsdcyclin D1 and cyclin E, in ovarian cancer cellFig. 10. Time effect of estrogen (0.1 mMlines to explore other possible mechanisms contributing to the
decreased survival of ovarian cancer cell lines after estrogen
treatment. Cyclin D was reported to play a dominant role in
regulating cell cycle progression in ovarian cancer, and
degradation of cyclin D1 is sufficient to induce G1 cell cycle
arrest.43 Cyclin E has been shown to compensate for knockout
of cyclin D during fetal development,44 and under normal
conditions, expression of cyclin E is controlled by cyclin D
through activation of CDK4/6 hypophosphorylation of
pRb.45,46 However, in this study, we did not find a change in
the expression of cyclins D1 and E in either cell line, sug-
gesting that the suppression of cell growth in the ovarian
cancer cell linesdeither ER-positive OVCAR3 cells or ER-
negative OC-117-VGH cellsdafter estrogen treatment might
not involve these two types of proteins.
By contrast, inhibitory proteins in the cell cycle, including
p16/INK4a and p27/KIP1, seemed to be dramatically altered
in this study. In addition, ER-positive and ER-negative ovarian
cancer cell lines showed a different response after estrogen
treatment. Estrogen exerted its growth suppression effects on
OC-117-VGH cells in this study by acting on the G1/S cell
checkpoints, because estrogen upregulated p27/KIP1 expres-
sion in the OC-117-VGH cells. Increased p27/KIP1 expression) on the expression of p16 (n¼ 6).
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a decrease in the levels of Skp2 and cyclin E, and cyclin A/
CDK2 activity and blocks the entry of cells in the G1 to S
phase.45 However, this phenomenon of an increased p27/KIP1
expression in the OC-117-VGH cell line was not found in the
ER-positive ovarian cancer cell lines, because estrogen-treated
OVCAR3 cells in serial concentrations or serial time expo-
sures did not show altered p27/KIP1 expression.
Our observation when we studied p16/INK4a expression in
ovarian cancer cell lines treated with estrogen was similar to
that of p27/KIP1 expression. The ER-negative OC-117-VGH
cell line showed a significant increase in p16/INK4a expres-
sion after estrogen treatment, and this effect was also shown as
dose- and time-dependent. Inactivation of p16/INK4a results
in loss of inhibition of retinoblastoma phosphorylation, facil-
itating a loss of control of cell cycle arrest.45 For example,
MDA-MB-453, one of the breast cancer cell lines, and one that
is androgen-positive and “triple-negative” with respect to
ERa, progesterone receptor and Her-2/neu protein expression,
and characterized as having a loss of the p16/INK4a gene, as
evidenced by the lack of p16/INK4a protein expression in
Western blot analysis and immunocytochemistry assays,
showed a rapid cell growth pattern and possessed highly
invasive and migratory behavior.46 However, this phenomenon
of an increased p16/INK4a expression in the ER-negative OC-
117-VGH cell line was not found in the ER-positive ovarian
cancer cell line, because estrogen-treated OVCAR3 cells in
serial concentrations or serial time exposures did not show
altered p16/INK4a expression, suggesting that the possible
pathways of growth suppression after estrogen treatment of
ER-positive and ER-negative ovarian cancer cell lines might
be different, respectively.
Regarding study limitations, as the OVCAR3 cell line is
positive for ERs, the effects of estrogen on cell survival may
be mediated through the classic estrogen/ER pathway, which
means that estrogen passes into the cytoplasm and binds ER
and enters into the nucleus with binding DNA and activates
the estrogen response elements.27,28 However, we did not
examine the classic estrogen/ER pathway to prove our
observation that estrogen decreased survival and/or growth in
the OVCAR3 cells. We also failed to detect the typical
morphologic characteristics of apoptosis, such as compaction
and margination of chromosomes, nuclear fragments, and the
formation of apoptotic bodies in our previous study16 and this
study (data not shown), although growth suppression was
prominent herein. Therefore, it was difficult to claim that the
decreased survival and/or growth may have been due to factors
other than cytotoxicity, although similar studies using the
different ER-positive cell lineseSKOV-3 confirmed these
effects might not be mediated by cytotoxicity.16,40 The
decreased human cancer cell population in vitro, as observed
in this study, reflects a change in the balance of the cell cycle
and could involve arrested cell proliferation, enhanced cell
death, or both, at least in the ER-negative OC-117-VGH cell
line; however, we did not identify which one was predominant.
In conclusion, the current study indicated that estrogen did
impair tumor survival in the ER-negative OC-117-VGH andER-positive OVCAR3 ovarian cancer cell lines. Although
estrogen-induced upregulation of p16/INK4a and p27/KIP1
proteins was found only in the ER-negative OC-117-VGH cells,
and not in the ER-positive OVCAR3 cells, our results supposed
the possibility of relationship between estrogen and ovarian
cancer, regardless of the presence or absence of ER expression.
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